Researchers at the University of North Carolina have developed a new immunotherapy approach that could significantly improve treatment for acute myeloid leukemia (AML), a deadly blood cancer. The team, led by immunologist Gianpietro Dotti and hematologist Paul Armistead, engineered immune cells capable of selectively targeting and destroying leukemia cells while leaving healthy blood tissue unharmed. This overcomes a major limitation of standard treatments, which often struggle to distinguish between cancerous and normal cells, leading to severe side effects.
The findings, published in the journal Blood, represent a promising step toward more targeted and less toxic cancer therapies. AML is an aggressive cancer that originates in the bone marrow and progresses rapidly. Current treatments, such as chemotherapy and stem cell transplants, can be effective but often damage healthy cells, causing significant toxicity. The new approach uses genetically modified T cells, a type of immune cell, that are engineered to recognize a specific protein found on AML cells but not on healthy blood cells.
According to the researchers, these engineered T cells demonstrated potent anti-leukemic activity in preclinical models, effectively eliminating cancer cells while preserving normal blood cell production. This precision targeting could reduce the harsh side effects associated with conventional therapies and improve patient outcomes. The study highlights the potential for developing "off-the-shelf" immunotherapies that could be used for a broader range of patients.
The research aligns with ongoing efforts by companies like Calidi Biotherapeutics Inc. (NYSE American: CLDI) to advance cancer treatments. Calidi is focused on developing stem cell-based platforms for delivering oncolytic viruses to tumors, aiming to enhance efficacy and reduce side effects. The convergence of such approaches could lead to more effective and safer cancer therapies.
While the UNC findings are preliminary, they offer hope for AML patients who have limited treatment options. The next steps involve further preclinical testing and eventual clinical trials to assess the therapy's safety and efficacy in humans. If successful, this engineered immunotherapy could become a cornerstone of AML treatment, providing a targeted alternative to traditional chemotherapy.
